Mridu Gulati, MD
Pulmonary Disease · New Haven, CTNPI 1548243629
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), speaking fees and grants — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 94.4% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $18,019, 2.2 times the $8,191 reported in 2019. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $760.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$50K
- Genentech, Inc.$3K
Across 42 payments — averaging $11,489 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$252K
- Boehringer Ingelheim$231K
What the payments were for
- Consulting fees$30,29557%
- Speaking & faculty fees$15,00328%
- Grants$3,0006%
- Travel & lodging$2,9446%
- Food & beverage$1,9634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 69 | $50,205 |
| Genentech, Inc. | 1 | $3,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$30,603
How this compares
$53,205 in reported general payments places this provider in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 125 | $1,624,531 |
| Pirfenidone | 25 | $69,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $54,295 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,151 |
| Mycophenolate Mofetil | 116 | $10,861 |
| DuleraMometasone/Formoterol | 15 | $5,403 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $5,138 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,729 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,304 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,219 |
| Prednisone | 157 | $649 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 80 | $546 |
| Famotidine | 27 | $322 |
| Fluticasone Propionate | 20 | $303 |
| Ipratropium Bromide | 21 | $273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $50,205 | $1,624,531125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Haven
- Geoffrey ChuppNew Haven$1.2M
- Michael ImevboreNew Haven$323K
- Naftali KaminskiNew Haven$180K
- Lauren CohnNew Haven$134K
- Erica HerzogNew Haven$74K
- Jennifer PossickNew Haven$48K
- Carolyn RochesterNew Haven$29K
- Maor SaulerNew Haven$18K
- Jonathan KoffNew Haven$15K
- Olurotimi AdekoluNew Haven$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.